Ortho-Clinical and Caprion in deal on vCJD (variant-Creutzfeldt- Jakob disease) blood test
This article was originally published in Clinica
An agreement to develop what might become the world's first human blood test for variant CJD has been struck between Johnson & Johnson subsidiary Ortho-Clinical Diagnostics (OCD) and Canadian company Caprion Pharmaceuticals. The deal, an extension of an R&D collaboration between the two, will give Raritan, New Jersey-based OCD exclusive worldwide marketing and distribution rights to the product for human IVD applications.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.